Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

About this update from Abeona Therapeutics Inc.

[{"type":"text","content":"CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Following the optimization of a release assay in 2025, ZEVASKYN commercial launch activities commenced in the fourth quarter, with the first patient treatment completed in December prior to a mandatory scheduled facility shutdown. Since resuming manufacturing in late January 2026, multiple biopsies have been collected, a patient has completed treatment with ZEVASKYN, and there are ongoing manufacturing runs. Additional biopsies are scheduled for the remainder of this quarter. “We are building toward a regular cadence of biopsy collections and are gaining visibility into more patients entering the ZEVASKYN treatment funnel,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. “As a result of this momentum, our initial Qualified Treatment Centers (QTCs) are becoming familiar with navigating the administrative process and we are observing growing interest in ZEVASKYN among patients and physicians. We anticipate these early positive patient experiences to catalyze sustained demand for ZEVASKYN.” Strong access momentum; driving continued payer engagement and provider readiness Policies covering ZEVASKYN have been published by all major commercial payers including United Healthcare, Cigna, Aetna, Anthem, and most Blue Cross Blue Shield plans, that account for 80 percent of lives covered by commercial insurance, signaling broad and early market acceptance. ZEVASKYN has also secured coverage across all Medicaid programs. In addition, the Centers for Medicare and Medicaid Services (CMS) has established a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for ZEVASKYN, J3389 (Topical administration, prademagene zamikeracel, per treatment), effective January 1, 2026. A J-code plays a vital role in streamlining the medical billing and reimbursement processes related to drug administration. About recessive dystrophic epidermolysis bullosaRecessive dystrophic epidermolysis bullosa (RDEB), a rare blistering disorder without a cure, is characterized by sev...

More updates from Abeona Therapeutics Inc.